Seminars in Oncology
Volume 29, Issue 4 , Pages 370-381 , August 2002

Pathologic staging of melanoma

References 

  1. Balch CM, Buzaid AC, Atkins MB, et al.  A New Americal Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000;88:1484–1491
  2. Balch CM, Buzaid AC, Soong SJ, et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648
  3. Ruiter DJ, Testori A, Eggermont AMM, et al.  The AJCC staging proposal for cutaneous melanoma: Comments by the EORTC Melanoma Group. Ann Oncol. 2001;12:9–11 (editorial)
  4. Ruiter DJ, Spatz A, Vanden Oord JJ, et al.  Microstaging of melanoma. J Pathol. 2001;195:526–530 (editorial)
  5. Clark WHJ, Elder DE, Guerry D, et al.  Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893–1904
  6. Allen AC, Spitz S. Malignant melanoma. A clinico-pathological analysis of the criteria for diagnosis and prognosis. Cancer. 1953;6:1–45
  7. Thompkins VN. Cutaneous melanoma:ulceration as a prognostic sign. Cancer. 1953;6:1215–1218
  8. Balch CM, Soong SJ, Milton GW, et al.  A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg. 1982;196:677–684
  9. Balch CM, Soong SJ, Murad TM, et al.  A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery. 1979;86:343–351
  10. Balch CM, Soong SJ, Murad TM, et al.  A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol. 1983;1:126–134
  11. Balch CM. Cutaneous melanoma: Prognosis and treatment results worldwide. Semin Surg Oncol. 1992;8:400–414
  12. Balch CM, Soong S, Ross MI, et al.  Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7:87–97
  13. Balch CM, Soong SJ, Gershenwald JE, et al.  Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622–3634
  14. Balch CM, Wilkerson JA, Murad TM, et al.  The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980;45:3012–3017
  15. Gershenwald JE, Thompson W, Mansfield PF, et al.  Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976–983
  16. Shaw HM, Balch CM, Soong , et al.  Prognostic histopathological factors in malignant melanoma. Pathology. 1985;17:271–274
  17. Soong SJ, Shaw HM, Balch CM, et al.  Predicting survival and recurrence in localized melanoma: A multivariate approach. World J Surg. 1992;16:191–195
  18. Urist MM, Balch CM, Soong , et al.  The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer. 1985;55:1398–1402
  19. McGovern VJ, Shaw HM, Milton GW, et al.  Ulceration and prognosis in cutaneous malignant melanoma. Histopathology. 1982;6:399–407
  20. Balch CM, Soong SJ, Bartolucci AA, et al.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255–263
  21. Cascinelli N, Marubini E, Morabito A, et al.  Prognostic factors for stage I melanoma of the skin: A review. Stat Med. 1985;4:265–278
  22. Averbook BJ, Russo LJ, Mansour EG. A long-term analysis of 620 patients with malignant melanoma at a major referral center. Surgery. 1998;124:746–755
  23. Heaton KM, Sussman JJ, Gershenwald JE, et al.  Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol. 1998;5:322–328
  24. Kim SH, Garcia C, Rodriguez , et al.  Prognosis of thick cutaneous melanoma. J Am Coll Surg. 1999;188:241–247
  25. MacKie RM, Carfrae DC, Cochran AJ. Assessment of prognosis in patients with malignant melanoma. Lancet. 1972;2:455–456
  26. MacKie RM, Aitchison T, Sirel JM, et al.  Prognostic models for subgroups of melanoma patients from the Scottish Melanoma Group database 1979-86, and their subsequent validation. Br J Cancer. 1995;71:173–176
  27. Marghoob AA, Koenig K, Bittencourt FV, et al.  Breslow thickness and clark level in melanoma: Support for including level in pathology reports and in American Joint Committee on Cancer Staging. Cancer. 2000;88:589–595
  28. Masback A, Westerdahl J, Ingvar C, et al.  Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985. Prognostic factors and histologic correlations. Cancer. 1997;79:275–283
  29. Masback A, Olsson H, Westerdahl J, et al.  Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res. 2001;11:435–445
  30. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet , et al.  Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch Dermatol. 1998;134:983–987
  31. Wagner JD, Gordon MS, Chuang TY, et al.  Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer. 2000;89:453–462
  32. Otto FJ, Goldmann T, Biess B. Prognostic classification of malignant melanomas by combining clinical, histological, and immunohistochemical parameters. Oncology. 1999;56:208–214
  33. Ferrier CM, Suciu S, van Geloof WL, et al.  High tPA-expression in primary melanoma of the limb correlates with good prognosis. Br J Cancer. 2000;83:1351–1359
  34. Barnhill RL, Fine JA, Roush GC, et al.  Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer. 1996;78:427–432
  35. Drzewiecki KT, Frydman H, Andersen K, et al.  Malignant melanoma. Changing trends in factors influencing metastasis-free survival from 1964 to 1982. Cancer. 1990;65:362–366
  36. Johnson TM, Dolan OM, Hamilton TA, et al.  Clinical and histologic trends of melanoma. J Am Acad Dermatol. 1998;38:681–686
  37. Thorn M, Ponten F, Bergstrom R, et al.  Trends in tumour characteristics and survival of malignant melanoma 1960-84: A population-based study in Sweden. Br J Cancer. 1994;70:743–748
  38. McMasters KM, Wong SL, Edwards MJ, et al.  Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery. 2001;130:151–156
  39. Finley JW, Gibbs JF, Rodriguez LM, et al.  Pathologic and clinical features influencing outcome of thin cutaneous melanoma: Correlation with newly proposed staging system. Am Surg. 2000;66:527–531
  40. Cascinelli N, Clemente C, Bifulco C, et al.  Do patients with tumor-positive sentinel nodes constitute a homogeneous group?. Ann Surg Oncol. 2001;8:35S–37S
  41. Eggermont AMM, Keilholz U, Testori A, et al.  The EORTC Melanoma Group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. Ann Surg Oncol. 2001;8:38–40
  42. Vollmer RT. Malignant melanoma. A multivariate analysis of prognostic factors. Pathol Ann. 1989;24:383–407
  43. Ostmeier H, Fuchs B, Otto F, et al.  Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma?. Cancer. 1999;85:2391–2399
  44. Karjalainen JM, Eskelinen MJ, Nordling , et al.  Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma. Br J Cancer. 1998;77:1917–1925
  45. Spatz A, Shaw HM, Crotty KA, et al.  Analysis of histopathological factors associated with prolonged survival of 10 years or more for patients with thick melanomas (> 5 mm). Histopathology. 1998;33:406–413
  46. Cook MG, Spatz A, Brocker EB, et al: Identification of histological features associated with metastatic potential in thin (<1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group. J Pathol (in press)
  47. Lock-Andersen J, Hou-Jensen K, Hansen JP, et al.  Observer variation in histological classification of cutaneous malignant melanoma. Scand J Plast Reconstr Surg Hand Surg. 1995;29:141–148
  48. Corona R, Mele A, Amini M, et al.  Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol. 1996;14:1218–1223
  49. Heenan PJ, Matz LR, Blackwell JB, et al.  Inter-observer variation between pathologists in the classification of cutaneous malignant melanoma in western Australia. Histopathology. 1984;8:717–729
  50. Busam KJ. Lack of relevant information for tumor staging in pathology reports of primary cutaneous melanoma. Am J Clin Pathol. 2001;115:743–746
  51. Korabiowska M, Brinck U, Mirecka J, et al.  Antigen Ki-67 and c-myc oncogene as related to histoclinical parameters in pigmented skin lesions. In Vivo. 1995;9:433–438
  52. Ross DA, Wilson GD. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma. Br J Surg. 1998;85:46–51
  53. Shih IM, Herlyn M. Autocrine and paracrine roles for growth factors in melanoma. In Vivo. 1994;8:113–123
  54. Ruiter DJ, Bogenrieder T, Elder D, et al.  Melanoma-stroma interactions. Structural and functional aspects. Lancet Oncol. 2002;3:25–33
  55. Shivers SC, Wang X, Li W, et al.  Molecular staging of malignant melanoma: Correlation with clinical outcome. JAMA. 1998;280:1410–1415
  56. Battayani Z, Grob JJ, Xerri L, et al.  Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol. 1995;131:443–447
  57. Pittman K, Burchill S, Smith B, et al.  Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol. 1996;7:297–301
  58. Kunter U, Buer J, Probst M, et al.  Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst. 1996;88:590–594
  59. Seiter S, Rappl G, Tilgen W, et al.  Facts and pitfalls in the detection of tyrosinase mRNA in the blood of melanoma patients by RT-PCR. Recent Results Cancer Res. 2001;15S:105–112
  60. Taback B, Morton DL, O'Day SJ, et al.  The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. Recent Results Cancer Res. 2001;15S:78–92
  61. Hoon DS, Bostick P, Kuo C, et al.  Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 2000;60:2253–2257
  62. Van Belle PA, Elenitsas R, Satyamoorthy K, et al.  Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol. 1999;30:562–571
  63. Hieken TJ, Ronan SG, Farolan M, et al.  Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer. 1999;85:375–382
  64. Hofmann UB, Westphal JR, Van-Muijen GN, et al.  Matrix metalloproteinases in human melanoma. J Invest Dermatol. 2000;115:337–344
  65. Vaisanen A, Kallioinen M, Taskinen PJ, et al.  Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol. 1998;186:51–58
  66. Vlaykova T, Laurila P, Muhonen T, et al.  Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. Melanoma Res. 1999;9:59–68
  67. Salti GI, Manougian T, Farolan M, et al.  Micropthalmia transcription factor: A new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res. 2000;60:5012–5016
  68. van den Oord JJ, Maes A, Stas M, et al.  CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol. 1996;149:1953–1961
  69. Demunter A, Stas M, Degreef H, et al.  Analysis of N- and K-ras mutations in the distinctive tumor progression phases of malignant melanoma. J Invest Dermatol. 2001;117:1483–1489
  70. Demunter A, Ahmadian MR, Libbrecht L, et al.  A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res. 2001;61:4916–4922
  71. Muller MGS, van Leeuwen PAM, de Lange-de Klerk ESM, et al.  The sentinel node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma. Cancer. 2001;91:2401–2408
  72. Starz H, Balda B-R, Krämer K-U, et al.  A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer. 2001;91:2110–2121
  73. Blaheta H, Ellwanger U, Schittek B, et al.  Examination of regional lymph nodes by sentinel node biopsy and mlecular analysis provides new staging facilities in primary cutaneous melanoma. Invest Dermatol. 2000;114:637–642
  74. van der Velde-Zimmerman D, Schipper MEI, de Weger RA, et al.  Sentinel node biopsies in melanoma patients: A protocol for accurate, efficient, and cost-effective analysis by preselection for immunohistochemistry on the basis of Tyr-PCR. Ann Surg Oncol. 2000;7:51–54
  75. Cochran AJ, Wen D-R, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. A immunohistological study. Am Surg Pathol. 1988;12:612–618
  76. Cochran AJ. Surgical pathology remains pivotal in the evaluation of ‘sentinel’ lymph nodes. Am Surg Pathol. 1999;23:1169–1172
  77. Bieligk SC, Klimstra DS, Rosai J, et al.  The detection of micrometastases in melanoma sentinel nodes by step-sectioning and immunohistochemical staining. Melanoma Res. 1997;7(suppl 1):S125; abstr
  78. Shivers SC, Wang X, Weiguo , et al.  Molecular staging of malignant melanoma. Correlation with clinical outcome. JAMA. 1998;280:1410–1415
  79. Gogel BM, Kuhn JA, Ferry KM, et al.  Sentinel lymph node biopsy for melanoma. Am Surg Pathol. 1998;176:544–547
  80. Bieligk SC, Ghosein R, Bhattacharya S, et al.  Detection of tyrosinase mRNA by reverse transcription-polymerase chain reaction in melanoma sentinel nodes. Ann Surg Oncol. 2001;6:232–240
  81. Hauschild A, Christophers E. Sentinel node biopsy in melanoma. Virchows Arch. 2001;438:99–106
  82. Messina JL, Glass LF, Cruse CW, et al.  Pathologic examination of the sentinel lymph node in malignant melanoma. Am Surg Pathol. 1999;23:686–690
  83. Clary BM, Brady MS, Lewis JJ, et al.  Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence. Ann Surg. 2001;233:250–258
  84. Joseph E, Brobeil A, Glass F, et al.  Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. Ann Surg Oncol. 1998;5:119–125
  85. Bostick PJ, Morton DL, Turner RR, et al.  Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol. 1999;17:3238–3244
  86. Miliotes G, Albertini J, Berman , et al.  The tumor biology of melanoma nodal metastases. Am Surg. 1996;62:81–88

☆ Supported in part by the EORTC Melanoma Cooperative Group.

☆☆ Address reprint requests to Professor Dirk J. Ruiter, Department of Pathology, University Medical Center St Radboud, PO Box 9101, 6500 HB Nijmegen, The Netherlands.

PII: S0093-7754(02)50267-0

doi: 10.1053/sonc.2002.34116

Seminars in Oncology
Volume 29, Issue 4 , Pages 370-381 , August 2002

Article Tools

* Image Usage & Resolution